Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Interview med CEO Thomas K. Selsø fra Pharma Equity Group - Hvad skete der i 1. kvartal?

By Claus ThestrupCEO, Sweden
Pharma Equity Group

Pharma Equity Group havde første handelsdag den 28. marts 2023 på Nasdaq København. De har netop aflagt deres 1. kvartalsregnskab for 2023.

Hvad er Pharma Equity Group for et selskab, og hvorfor købte de selskabet Reponex Pharmaceuticals?  Dette og flere andre spørgsmål besvarer CEO Thomas K. Selsø i dette interview.

Lyt til interview her: https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-q1-kvartalsregnskabet-2023

Disclaimer:

HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. /ANALYTIKER Claus Thestrup  kl. 11:00 d. 15/5-2023

Login required

This content is only available for logged in users

Create account

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.